A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)

A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol-related liver disease.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof William Kemp

Key inclusion data

Inclusion: Have a clinical diagnosis of liver cirrhosis in the participant’s medical history corroborated by previous liver biopsy, medical imaging or compatible biochemical profile, and − Be consistently classed during screening as one of the following CTP classes: o CTP A: Score 5-6; or CTP B: Score 7-9. o Additional exploratory group CTP C: Score >9. Exclusion criteria: Self-reported alcohol abstinence ≥4 months prior to Screening 1. A positive local blood PEth result from testing within 3 months prior to Screening 1 is acceptable to exclude abstinence. Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD)